<DOC>
	<DOCNO>NCT00043147</DOCNO>
	<brief_summary>RATIONALE : Beclomethasone combine prednisone may effective treatment graft-versus-host disease cause stem cell transplantation . It yet know prednisone effective without beclomethasone treat gastrointestinal graft-versus-host disease . PURPOSE : Randomized phase III trial determine effectiveness prednisone without beclomethasone treat patient graft-versus-host disease afftecting gastrointestinal system .</brief_summary>
	<brief_title>Beclomethasone Plus Prednisone Treating Patients With Graft-Versus-Host Disease</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy beclomethasone dipropionate prednisone v placebo prednisone , term time treatment failure , patient grade II graft-vs-host disease gastrointestinal symptom . - Compare proportion treatment failure study day 10 , 30 , 50 , 60 , 80 patient treated regimen . - Compare cumulative systemic corticosteroid exposure patient treat regimen . - Compare incidence degree hypothalamic-pituitary-adrenal axis suppression patient treat regimen experience treatment failure study day 50 . - Compare safety regimens patient . - Compare total deaths cause death 200 day post-transplantation patient treat regimen . - Assess pharmacokinetic profile beclomethasone dipropionate patient . OUTLINE : This randomize , double-blind , placebo-controlled , parallel , multicenter study . Patients stratify accord graft tissue source ( 2 HLA haplotype-identical sibling v others ) topical steroid use baseline ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral beclomethasone dipropionate 4 time daily day 1-50 . Patients also receive oral prednisone ( methylprednisolone IV ) twice daily day 1-10 rapid taper day 11-17 follow low-dose prednisone day 18-80 . - Arm II : Patients receive oral placebo 4 time daily day 1-50 . Patients also receive prednisone ( methylprednisolone ) arm I . In arm , treatment continue absence poorly control GVHD day 10 unacceptable toxicity . Patients follow day 51 , 60 , 80 200 day post-transplantation . PROJECTED ACCRUAL : A total 130 patient ( 65 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm graftvshost disease ( GVHD ) gastrointestinal symptom Endoscopic evidence grade II intestinal GVHD without another plausible etiology Confirmed biopsy colon , stomach , small intestine , esophagus , skin within 72 hour prior study entry At least 10 day post allogeneic hematopoietic stem cell transplantation Received prior anticandidal prophylaxis oropharynx effective drug Confirmed absence intestinal infection within past 7 day No liver GVHD bilirubin great 3 mg/dL No skin GVHD slowly evolve rash involve 50 % body surface No 1,000 mL/day diarrhea 1 day within past 3 day PATIENT CHARACTERISTICS : Age Not specify Performance status Not specify Life expectancy At least 3 month Hematopoietic Not specify Hepatic See Disease Characteristics Renal Not specify Other HIV negative Able swallow tablet No multiorgan failure No sepsis syndrome No condition high mortality No infection mouth esophagus fungal organism No persistent vomit oral intake Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics At least 30 day since prior biologic agent Chemotherapy Not specify Endocrine therapy At least 30 day since prior systemic ( oral parenteral ) prescription corticosteroid administer prophylaxis treatment GVHD another inflammatory disease process Concurrent dexamethasone antiemetic lessen side effect medication blood product administration allow Radiotherapy Not specify Surgery See Disease Characteristics Other No prior beclomethasone dipropionate At least 30 day since prior investigational drug device Concurrent immunosuppressant ( e.g. , cyclosporine , tacrolimus , sirolimus , methotrexate , mycophenolate mofetil ) allow GVHD prophylaxis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2004</verification_date>
	<keyword>graft versus host disease</keyword>
</DOC>